A stealth reprioritizing of Urocidin......possibly underway in Endo's corporate literature. Not sure. But below are two links to two
"product pipeline"bar chartsshown on Endo's web site and likely with two different "as at" dates.
Link #1: (pipeline chart
dated 12/31/09 and found on page 2 of their "corporate fact sheet")
Urocidin is shown
fourth from the top and at the same Ph III level as their Octreotide Implant.